Plain-English translation of NCT05847569 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether lower or different dosing schedules of can treat advanced multiple myeloma while causing fewer side effects. Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow. This medication is designed to target and attack myeloma cells in patients whose cancer has become resistant to other standard treatments.
Previous studies of this medication showed it could help some patients with hard-to-treat multiple myeloma, but it sometimes caused eye problems (keratopathy). This trial is looking to see if using lower doses or spreading out treatment differently can maintain the cancer-fighting benefits while reducing these eye-related side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one receiving a lower dose of the medication every 6 weeks, or another receiving a different dosing schedule starting every 3 weeks then moving to every 6 weeks. You'll visit the clinic regularly for intravenous infusions, blood work, and imaging scans (CT, MRI, or PET scans) to monitor how well the treatment is working and watch for side effects. The study includes bone marrow samples and regular eye exams to check for any vision problems.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States